Clinical Trial

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-10-28; most recent amendment 2025-07-18.
Status change: Recruiting → Active, Not Recruiting 2025-07-18
Status change: Not Yet Recruiting → Recruiting 2023-08-16
Trial Details
NCT Number NCT05604560
Lead Sponsor Lei Zheng
Collaborators: BeiGene, Syntrix Biosystems, Inc.
Conditions Pancreatic Cancer
Enrollment 25 participants
Start Date 2023-11-08
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-07-23